TL;DR — Rapamycin inhibits mTORC1, the nutrient-sensing kinase that blocks autophagyThe cellular self-cleaning process that breaks down and recycles damaged proteins, organelles, and pathogens. Full glossary →. It is the most replicated pharmacological lifespan extension in mice — but human longevity use is off-label, prescription-only, and immunosuppressive at continuous doses. Tier B: strong preclinical + emerging human safety; no completed human longevity RCT. Physician supervision is mandatory.
What rapamycin does (and why it matters)
When nutrients and growth signals are abundant, mTORA kinase that acts as a cellular growth sensor — when inhibited, cells shift from growth mode into repair, recycling, and autophagy. Full glossary → Complex 1 (mTORC1) prioritizes protein synthesis and cell growth over repair. With age, this balance skews toward growth signaling — autophagy, mitophagyA specific form of autophagy that selectively removes damaged or dysfunctional mitochondria, replacing them with healthy ones. Full glossary →, and stress resistance stay suppressed even when cells need cleanup.
Rapamycin (sirolimus) binds FKBP12 and inhibits mTORC1, mimicking the repair-heavy state of caloric restriction without fasting.
Primary hallmarks targeted: Disabled macroautophagy · Deregulated nutrient sensing · Cellular senescence · Mitochondrial dysfunction
Harrison et al. Nature 2009 (PMID 19587683): rapamycin started late in life extended median and maximal lifespan in genetically heterogeneous mice. Mannick 2014 (PMID 25540326): low-dose mTOR inhibition improved immune function in elderly humans. No completed human longevity endpoint trial.
Educational module only — Rx compound
Rapamycin is an immunosuppressant at transplant doses. TNiC documents evidence for informed physician discussions — we do not prescribe, source, or recommend self-medication. Research-chemical sirolimus is never acceptable. See /trust/disclaimers.
Mechanism — growth off, repair on
| Effect | Mechanism | Hallmark |
|---|---|---|
| Autophagy induction | ULK1 activation when mTORC1 low | Disabled autophagy |
| Senescence modulation | Reduced SASPSenescence-Associated Secretory Phenotype — the inflammatory cocktail of cytokines, proteases, and growth factors secreted by senescent (zombie) cells. Full glossary → in some models | Cellular senescence |
| Nutrient sensing reset | Mimics caloric restriction signaling | Nutrient sensing |
| Mitophagy | Enhanced mitochondrial recycling | Mitochondrial dysfunction |
Pulse vs continuous dosing
Mouse longevity data used continuous low-dose exposure. Human longevity protocols often use intermittent pulse dosing (e.g., weekly) to reduce immunosuppression while maintaining autophagy windows. No consensus human protocol exists — prescribing physician sets schedule.
When rapamycin is even discussable
Rapamycin enters a physician conversation only when all apply:
- Established relationship with a prescriber experienced in off-label longevity use
- Baseline CBC, lipids, glucose, and LFTs on file
- Lifestyle foundation (sleep, exercise, nutrition) already running 8+ weeks
- OTC hallmark stack (GlyNAC, NMN) running as complementary — not substitutive
Not discussable for self-experimentation, research-chemical sourcing, or as first-line intervention before lifestyle and OTC evidence stacks.
Evidence summary
| Study | Model | Finding | Tier |
|---|---|---|---|
| Harrison 2009 (19587683) | Mice (heterogeneous) | ↑ median & maximal lifespan, late-life start effective | Preclinical → B |
| Bjedov 2010 (19587680) | Mice | Replicated lifespan extension | Preclinical |
| Mannick 2014 (25540326) | Humans (elderly) | Low-dose mTOR inhibition improved immune response | B |
| PEARL trial | Humans | Safety/pharmacokinetics at low doses | Emerging |
| Dog Aging Project | Dogs | Mid-life rapamycin safety study | Emerging |
← Swipe for more columns →
Consensus: Strongest preclinical lifespan drug. Human longevity outcomes unproven. Tier B for mechanistic + emerging human safety — not Tier A until longevity RCT completes.
Where rapamycin disappoints
- The human longevity case is extrapolation. The dramatic data are all mouse; the first completed low-dose human trials (e.g. PEARL) support tolerability but showed only modest, selective functional signals — not a proven healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary → effect. - The dosing is a guess. Mouse lifespan used continuous exposure; human "weekly pulse" protocols exist to limit immunosuppression, but no validated human schedule exists — you'd be self-selecting into an unproven regimen. - Real class side effects. Even intermittently it can cause mouth sores, impaired wound healing, new hyperglycemia, and dyslipidemia — the reason continuous dosing carries genuine cost.
Is rapamycin appropriate to discuss with your physician?
Licensed prescriber + baseline labs + lifestyle foundation 8+ weeks?
node | Specific hallmark targets need mTOR modulation (autophagy/nutrient sensing)?
Educational reference stack for physician review — never self-dose
Continue OTC stack + labs 12 weeks — reassess with physician
Do not pursue — fix foundation first; Rx without oversight is unacceptable
Active infection, planned surgery, live vaccines, pregnancy, or research-chemical sourcing → hard stop
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing paradigms (educational — physician sets actual dose)
Physician-supervised only
The following reflects published discussion protocols — NOT TNiC recommendations. Individual dosing requires medical oversight.
| Paradigm | Pattern | Rationale | Risk profile |
|---|---|---|---|
| Weekly pulse | 3–6 mg once weekly | Autophagy induction with recovery windows | Lower continuous immunosuppression |
| Bi-weekly | 3–6 mg every 2 weeks | Conservative entry | Lowest exposure |
| Continuous low | 1–2 mg daily | Closer to mouse model | Higher infection/metabolic risk |
← Swipe for more columns →
Supporting OTC stack (TNiC educational combo): GlyNAC + NMN + Ca-AKG addresses complementary hallmarks while physician manages rapamycin.
Physician visit checklist
- [ ] Bring this module + Rapamycin Combo stack from Stack Architect
- [ ] Baseline CBC, fasting lipids, glucose, HbA1c, LFTs printed
- [ ] Document infection history and vaccination schedule
- [ ] Agree pulse vs continuous in writing
- [ ] Schedule 3-month lab cadence before first dose
View educational Rapamycin combo
Reference stack for physician discussions — Rx compound flagged, monitoring checklist included.
Rapamycin Combo stackMonitoring (physician-managed)
| Test | Frequency | Red flag |
|---|---|---|
| CBC with differential | Every 3 months | WBC <4.0, neutropenia |
| Fasting lipids | Every 3–6 months | Triglycerides >400, LDL spike |
| Fasting glucose / HbA1c | Every 3–6 months | New-onset hyperglycemia |
| Oral mucosal exam | Monthly self-check | Mouth sores (mTOR inhibitor class effect) |
| Infection vigilance | Ongoing | Recurrent infections, slow wound healing |
| LFTs | Baseline, 3 months | Elevated transaminases |
CBC
WBC in range
Lipids
Baseline
Fasting glucose
<100 mg/dL
Infections
None
CBC
No neutropenia trend
Lipids
No TG >400 spike
Fasting glucose
No new hyperglycemia
Infections
None — vigilance ongoing
Track labs locally
Log CBC and metabolic markers alongside physician orders — TNiC does not replace clinical monitoring.
Open Labs hubSafety, red flags, and contraindications
Absolute contraindications (discuss with physician): - Active infections - Live vaccines during treatment - Planned surgery (wound healing impairment) - Severe hepatic impairment - Pregnancy
Drug interactions: CYP3A4 metabolism — strong inhibitors (azole antifungals) increase levels; inducers decrease efficacy.
Hard stops — never self-medicate
- Research-chemical sirolimus — only pharmacy-grade via prescriber
- Skipping CBC because dose feels low — immunosuppression is dose- and individual-dependent
- Continuous daily dosing without monitoring plan — metabolic and infection risks accumulate
- OTC stack substitution — NAD+ and antioxidants do not eliminate rapamycin risks
What would change this grade. Rapamycin is B — unmatched preclinical data, no completed human longevity endpoint. A positive human healthspan/longevity RCT would move it to A; expanded PEARL-style functional data could firm up the safety case. It would fall if human trials confirm meaningful risk without matching benefit.
Who should skip rapamycin
- Anyone without an experienced prescriber and a lab-monitoring plan — this is an immunosuppressant, not a supplement to self-run. - Active infection, planned surgery, live vaccines, or pregnancy — hard contraindications. - Anyone considering research-chemical sirolimus — never acceptable; pharmacy-grade under prescription only.
Synergies and antagonists (complementary, not substitutive)
Pairs well with:
| Intervention | Relationship to rapamycin |
|---|---|
| GlyNAC / NRF2 stack | Antioxidant foundation; does not replace mTOR modulation |
| NMN | NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → support during autophagy-heavy periods |
| Caloric moderation | Parallel AMPK activation; additive nutrient sensing benefit |
| Exercise | Independent healthspan lever; maintain during protocol |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Strong CYP3A4 inhibitors (azole antifungals, some antibiotics) | Raise rapamycin blood levels into toxic range | Physician must manage — never combine unmonitored |
| CYP3A4 inducers (rifampin, St. John's wort) | Lower levels, undercutting efficacy | Disclose all meds/supplements to the prescriber |
| Live vaccines / other immunosuppressants | Additive immunosuppression and blunted vaccine response | Coordinate timing with your physician |
Personal results template (physician-supervised)
My rapamycin protocol log (Rx only)
| Date | Dose | Schedule | CBC OK? | Lipids OK? | Infections | Energy (1–10) | Physician notes |
|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | — mg | — | — | — | None | — | Baseline labs |
| YYYY-MM-DD | — mg | Weekly | Yes/No | Yes/No | — | — | 3-month review |
← Swipe for more columns →
Never self-adjust dose. All changes require prescribing physician approval.
Read full disclaimers
Rx compound policy, educational use only, and physician consultation requirements.
Trust Center disclaimersReferences
- PMID 19587683
- See PMID registry. Low-dose rapamycin partially reverses immune aging in humans. Immunity & aging (2023). PMID 25540326
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.